You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Moodys
AstraZeneca
Medtronic
Express Scripts

Last Updated: February 20, 2020

DrugPatentWatch Database Preview

Litigation Details for Forest Laboratories LLC v. Sigmapharm Laboratories LLC (D. Del. 2014)


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Forest Laboratories LLC v. Sigmapharm Laboratories LLC (D. Del. 2014)

Docket   Start Trial Date Filed 2014-09-03
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Mitchell S. Goldberg
Jury Demand None Referred To
Parties ALEMBIC GLOBAL HOLDING S/A; ALEMBIC PHARMACEUTICALS INC.; ALEMBIC PHARMACEUTICALS LTD.; ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED; AMNEAL PHARMACEUTICALS CO. INDIA PVT. LTD.; AMNEAL PHARMACEUTICALS LLC; AMNEAL PHARMACEUTICALS OF NEW YORK LLC; BRECKENRIDGE PHARMACEUTICAL INC.; FOREST LABORATORIES HOLDINGS LTD.; FOREST LABORATORIES LLC; HIKMA PHARMACEUTICALS LLC; HIKMA PHARMACEUTICALS PLC; SIGMAPHARM LABORATORIES LLC; WEST-WARD PHARMACEUTICALS CORP.
Patents 5,763,476; 7,741,358; 8,022,228
Attorneys Aaron G. Clay; Aaron Gleaton Clay; Aiyda Ghahramani; Alton L. Hare , III; Anthony G. Simon; Anthony R. Friedman; Azy S. Kokabi; Benjamin R. Askew; Beth D. Jacob; Charles E. Lipsey; Christopher T. Griffith; Clifford E. Katz; David A. Bilson; Eve H. Ormerod; Helen H. Ji; Howard W. Levine; Imron T. Aly; Jack B. Blumenfeld; Jeffrey Thomas Castellano; Jennifer M. Rutter; Jeremy A. Tigan; Joel M. Wallace; John C. Phillips , Jr.; John E. Rosenquist; John K. Hsu; John Simon; Jonathan R. Davies; Karen Elizabeth Keller; Karen L. Pascale; Karen Shen; Ksenia Takhistova; Marc R. Wezowski; Maryellen Noreika; Megan C. Haney; Michael K. Levy; Michael P. Kella; Michael R. Dzwonczyk; Michael W. Glynn; Nathan Newbold; Neal C. Belgam; Nitya Anand; Paul M. Richter; Richard D. Kirk; Robert F. Green; Robert Karl Beste , III; Sanya Sukduang; Sara E. Bussiere; Seth R. Ogden; Stephen B. Brauerman; Steven J. Lee Ph.D.; Timothy D. Krieger; Vanessa Ribeiro Tiradentes
Firms Bayard, P.A.; Gould & Ratner LLP; Morris, Nichols, Arsht & Tunnell; Phillips, Goldman, McLaughlin & Hall, P.A.; Shaw Keller LLP; Smith, Katzenstein, & Jenkins LLP; Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Forest Laboratories LLC v. Sigmapharm Laboratories LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Forest Laboratories LLC v. Sigmapharm Laboratories LLC (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2018-11-16 409 assignee of U.S. Patent Nos. 5,763,476 (“the ’476 patent”), 7,741,358 (“the ’358 patent”), and 8,022,228…all three patents covering Saphris®—i.e., the ’476 patent, the ’358 patent, and the ’228 patent. (D.I. …infringement of two of the three patents covering Saphris®—the ’476 patent and ’358 patent. (D.I. 1, C.A. No.…counterclaims seeking a declaration that the ’358 patent and ’228 patent were invalid. (Id.). As a result, the …and 10 of the ’476 patent. (Id.). Finally, Judge Robinson held that the ’476 patent was valid and entered External link to document
2018-12-06 416 infringed U.S. Patent Nos. 5,763,476 (“the ’476 patent”). (D.I. 409; D.I. 410). The ’476 patent is assigned…Forest asserted that Sigmapharm infringed the ’476 patent both literally and under the doctrine of equivalents…’s accused product literally infringed the ’476 patent, I did not address the parties’ arguments regarding…to its ANDA intended to design around the ’476 patent. (D.I. 411 at 3; D.I. 411-1). Sigmapharm cites …by principles of fairness and prejudice to the patent-holder,” to reconsider a finding of infringement External link to document
2019-08-06 458 Opinion - Memorandum Opinion defendants infringed claim 1 of U.S. Patent No. 5,763,476 (“the ’476 patent”), which requires that the pharmaceutical… In September 2014, Forest initiated several patent infringement actions against companies that had…infringed claims 1-2, 4-6, and 9-10 of the ’476 patent. (D.I. 384-1, Ex. 4). The parties agreed that …whether Sigmapharm infringed claim 1 of the ’476 patent either literally or under the doctrine of equivalents…Sigmapharm literally infringed claim 1 of the ’476 patent. (D.I. 409). Because I found that Forest proved External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Baxter
McKesson
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.